Search research articles
Contact Us
Filters
Showing results (11-20 of 27) with videos related to
Page
of 3
Sort By:
The Journal of Clinical Psychiatry
|
June 7, 2018
A Randomized, Placebo-Controlled Study of the Efficacy and Safety of Fixed-Dose Brexpiprazole 2 mg/d as Adjunctive Treatment of Adults With Major Depressive Disorder
Mary Hobart, Aleksandar Skuban, Peter Zhang, et al.
Current Medical Research and Opinion
|
June 9, 2026
Benefits and safety of brexpiprazole in adolescents living with schizophrenia: a plain language summary
Caroline Ward, Milica Pejović Milovančević, Nanco Hefting, et al.
Acta Neuropsychiatrica
|
November 19, 2024
A randomised study and an extension study of brexpiprazole in patients with borderline personality disorder
Brian Rothman, Claudette Brewer, Denise Chang, et al.
The Journal of Clinical Psychiatry
|
March 2, 2022
Effects of Brexpiprazole on Functioning in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies
Christoph U Correll, Ying He, François Therrien, et al.
Acta Neuropsychiatrica
|
October 17, 2024
A double-blind, placebo-controlled, randomised withdrawal study of adjunctive brexpiprazole maintenance treatment for major depressive disorder
Roger S McIntyre, Kripa Sundararajan, Saloni Behl, et al.
JAMA Psychiatry
|
December 18, 2024
Brexpiprazole and Sertraline Combination Treatment in Posttraumatic Stress Disorder: A Phase 3 Randomized Clinical Trial
Lori L Davis, Saloni Behl, Daniel Lee, et al.
Journal of Child and Adolescent Psychopharmacology
|
February 19, 2025
Safety and Efficacy of Brexpiprazole in the Treatment of Irritability Associated with Autism Spectrum Disorder: An 8-Week, Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial and 26-Week Open-Label Extension in Children and Adolescents
Caroline Ward, Ann Childress, Krista Martinko, et al.
Current Medical Research and Opinion
|
January 19, 2018
Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: a randomized, active-referenced, placebo-controlled study
Mary Hobart, Aleksandar Skuban, Peter Zhang, et al.
Journal of Clinical Psychopharmacology
|
September 22, 2025
Fixed-Dose Brexpiprazole and Sertraline Combination Therapy for the Treatment of Posttraumatic Stress Disorder: A Phase 3, Randomized Trial
Lori L Davis, Saloni Behl, Daniel Lee, et al.
Clinical Drug Investigation
|
January 27, 2026
Efficacy of Brexpiprazole in Participants with Agitation Associated with Dementia Due to Alzheimer's Disease: Pooled Analysis of Randomized Controlled Trials
Jeffrey L Cummings, Sanjeda R Chumki, Denise Chang, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 27) with videos related to
Sort By:
Page
of 3
The Journal of Clinical Psychiatry
|
June 7, 2018
A Randomized, Placebo-Controlled Study of the Efficacy and Safety of Fixed-Dose Brexpiprazole 2 mg/d as Adjunctive Treatment of Adults With Major Depressive Disorder
Mary Hobart, Aleksandar Skuban, Peter Zhang, et al.
Current Medical Research and Opinion
|
June 9, 2026
Benefits and safety of brexpiprazole in adolescents living with schizophrenia: a plain language summary
Caroline Ward, Milica Pejović Milovančević, Nanco Hefting, et al.
Acta Neuropsychiatrica
|
November 19, 2024
A randomised study and an extension study of brexpiprazole in patients with borderline personality disorder
Brian Rothman, Claudette Brewer, Denise Chang, et al.
The Journal of Clinical Psychiatry
|
March 2, 2022
Effects of Brexpiprazole on Functioning in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies
Christoph U Correll, Ying He, François Therrien, et al.
Acta Neuropsychiatrica
|
October 17, 2024
A double-blind, placebo-controlled, randomised withdrawal study of adjunctive brexpiprazole maintenance treatment for major depressive disorder
Roger S McIntyre, Kripa Sundararajan, Saloni Behl, et al.
JAMA Psychiatry
|
December 18, 2024
Brexpiprazole and Sertraline Combination Treatment in Posttraumatic Stress Disorder: A Phase 3 Randomized Clinical Trial
Lori L Davis, Saloni Behl, Daniel Lee, et al.
Journal of Child and Adolescent Psychopharmacology
|
February 19, 2025
Safety and Efficacy of Brexpiprazole in the Treatment of Irritability Associated with Autism Spectrum Disorder: An 8-Week, Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial and 26-Week Open-Label Extension in Children and Adolescents
Caroline Ward, Ann Childress, Krista Martinko, et al.
Current Medical Research and Opinion
|
January 19, 2018
Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: a randomized, active-referenced, placebo-controlled study
Mary Hobart, Aleksandar Skuban, Peter Zhang, et al.
Journal of Clinical Psychopharmacology
|
September 22, 2025
Fixed-Dose Brexpiprazole and Sertraline Combination Therapy for the Treatment of Posttraumatic Stress Disorder: A Phase 3, Randomized Trial
Lori L Davis, Saloni Behl, Daniel Lee, et al.
Clinical Drug Investigation
|
January 27, 2026
Efficacy of Brexpiprazole in Participants with Agitation Associated with Dementia Due to Alzheimer's Disease: Pooled Analysis of Randomized Controlled Trials
Jeffrey L Cummings, Sanjeda R Chumki, Denise Chang, et al.
Page
of 3